SEARCH

SEARCH BY CITATION

References

  • 1
    Amé J-C , Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 88293.
  • 2
    Gudmundsdottir K , Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 586474.
  • 3
    Ashworth A . A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 378590.
  • 4
    Bryant HE , Schultz N, Thomas HDet al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 9137.
  • 5
    Farmer H , McCabe N, Lord CJet al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 91721.
  • 6
    McCabe N , Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4: 9346.
  • 7
    Hay T , Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005; 65: 101458.
  • 8
    Evers B , Drost R, Schut Eet al.Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 391625.
  • 9
    Rottenberg S , Jaspers JE, Kersbergen Aet al.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 1707984.
  • 10
    Fong PC , Boss DS, Yap TAet al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 12334.
  • 11
    Fong PC , Yap TA, Boss DSet al.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 25129.
  • 12
    Tutt A , Robson M, Garber JEet al.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 23544.
  • 13
    Audeh MW , Carmichael J, Penson RTet al.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 24551.
  • 14
    Gelmon KA , Hirte HW, Robidoux Aet al.Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol 2010; 28: abst 3002.
  • 15
    Therasse P , Arbuck SG, Eisenhauer EAet al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516.
  • 16
    Menear KA , Adcock C, Boulter Ret al.4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 658191.
  • 17
    Molife R , Kaye S, Forster Met al.A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. J Clin Oncol 2010; 28: abst 2599.
  • 18
    Ledermann J , Harter P, Gourley Cet al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 2011; 29: abst 5003.